Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate — Stella

Home/Primary Aldosteronism/

View on ClinicalTrials.gov

Recruiting

Back to Primary Aldosteronism trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Netherlands

University Medical Center Groningen, Groningen, Provincie Groningen

Key details

Phase

Early testing / Safety & dosing

Sponsor

University Medical Center Groningen

Enrollment target

~12 participants

Started

November 2024

Primary completion

October 2026

Age range

18 Years and older

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.